Skip to Main Content

Paper Details

Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
Prostate Cancer Prostatic Dis
5
2022
PSA, Patient, Patients, SSEs, mCRPC, men, metastatic castration-resistant prostate cancer, patient, patients, prostate-specific antigen, radium-223, visceral metastases
Author NameAffiliation
Neeraj AgarwalHuntsman Cancer Institute, University of Utah
Oliver SartorTulane Cancer Center, Tulane University School of Medicine
Cora N SternbergEnglander Institute for Precision Medicine, Meyer Cancer Center, New York-Presbyterian Hospital
Fred SaadUniversity of Montreal Hospital Center
Celestia S HiganoUniversity of Washington and Fred Hutchinson Cancer Research Center
  • 1 - 5

Datasets

Release 1.2